BioSpace News Archive

Arch Biopartners Inc. announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office to protect new antibody drug candidates that target inflammation in the lungs, liver and kidneys mediated by dipeptidase-1 (DPEP-1).

Kura Oncology, Inc. today announced its participation in the JMP Securities Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on Thursday, June 17, 2021.

Humacyte, Inc., today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat on regenerative medicine at the Cowen 6th Annual FutureHealth Conference taking place virtually on June 16, 2021, at 10 a.m. EDT.

Progenity, Inc. today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting of shares of common stock.

Ocugen, Inc. today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.

ACELYRIN, INC. today announced the appointment of Patrick (Pat) Machado , JD to its board of directors.

Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing.

Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license agreement to research both single- and multi-targeted CAR-T treatments to be used in combination with Vor’s engineered hematopoietic stem cell (eHSC) platform.

Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.

Device is FDA IDE approved to start a clinical study in the U.S. to investigate a novel cardiac arrest treatment indication.